Luciole Pharmaceuticals
Luciole Pharmaceuticals is a biotechnology startup focused on discovering and developing small molecule activators of OGG1, an enzyme that accelerates the repair of oxidative damage to mitochondrial DNA (mtDNA). The company leverages expertise in mitochondrial function, drug discovery, and a virtual company model to lead in correcting oxidative mtDNA damage, which is implicated in age-related diseases such as Alzheimer's, Parkinson's, ALS, obesity, and metabolic syndrome. Luciole collaborates with academic institutions and uses AI-driven drug discovery platforms to develop novel therapeutics targeting mitochondrial dysfunction and inflammation, aiming to prevent neurodegeneration and metabolic diseases.
Luciole Pharmaceuticals
Luciole Pharmaceuticals is a biotechnology startup focused on discovering and developing small molecule activators of OGG1, an enzyme that accelerates the repair of oxidative damage to mitochondrial DNA (mtDNA). The company leverages expertise in mitochondrial function, drug discovery, and a virtual company model to lead in correcting oxidative mtDNA damage, which is implicated in age-related diseases such as Alzheimer's, Parkinson's, ALS, obesity, and metabolic syndrome. Luciole collaborates with academic institutions and uses AI-driven drug discovery platforms to develop novel therapeutics targeting mitochondrial dysfunction and inflammation, aiming to prevent neurodegeneration and metabolic diseases.